LAMP1 and B-cell chronic lymphocytic leukemia: The pre-treatment of CLL cells with selinexor also enhanced NK cell activation as measured by both degranulation (increased CD107a positivity) (mean 5.26% at 0 nM rising to 9.35% at 500 nM, P < 0.005) and IFNγ expression (mean 0.54% at 0 nM rising to 1.23% at 500 nM, P < 0.05) (Fig. 1F–H).